Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia

Borja Guerra; Patricia Martín-Rodríguez; Juan Carlos Díaz-Chico; Grant McNaughton-Smith; Sandra Jiménez-Alonso; Idaira Hueso-Falcón; Juan Carlos Montero; Rosa Blanco; Javier León; Germán Rodríguez-González; Ana Estévez-Braun; Atanasio Pandiella; Bonifacio Nicolás Díaz-Chico; Leandro Fernández-Pérez

doi:10.18632/oncotarget.26008

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia

PDF | How to cite

Oncotarget. 2018; 9:32272-32272. https://doi.org/10.18632/oncotarget.26008

Metrics: PDF 1595 views | ?

Borja Guerra^1,2,3,*, Patricia Martín-Rodríguez^1,*, Juan Carlos Díaz-Chico^1,3, Grant McNaughton-Smith⁴, Sandra Jiménez-Alonso^3,7, Idaira Hueso-Falcón⁴, Juan Carlos Montero⁵, Rosa Blanco⁶, Javier León⁶, Germán Rodríguez-González⁴, Ana Estévez- Braun^3,7, Atanasio Pandiella⁵, Bonifacio Nicolás Díaz-Chico^1,3,4 and Leandro Fernández-Pérez^1,3

¹ Instituto de Investigaciones Biomédicas y Sanitarias BioPharm Laboratory, Universidad de Las Palmas de Gran Canaria, Epaña
² Unidad de Apoyo a la Docencia en Enfermería-Fuerteventura, Universidad de Las Palmas de Gran Canaria, España
³ Instituto Canario de Investigación sobre el Cáncer, España
⁴ Centro Atlántico del Medicamento, España
⁵ Centro de Investigación del Cáncer, CSIC, Universidad de Salamanca, España
⁶ Instituto de Biomedicina y Biotecnología de Cantabria, CSIC-Universidad de Cantabria, España
⁷ Departamento de Química Orgánica, Instituto de Bio-Orgánica Antonio González, Universidad de la Laguna, España
^* These authors contributed equally to this work

Published: August 14, 2018

This article has been corrected: The correct author name is given below:

Rosa Blanco

Original article: Oncotarget. 2017; 8:29679-29698. DOI: https://doi.org/10.18632/oncotarget.11425.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26008

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia